Drugs / Japanese encephalitis chimeric virus vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01092507 | Mar 2010 → Sep 2011 | Japanese encephalitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Japanese encephalitis chimeric virus vaccine | “Japanese encephalitis chimeric virus vaccine (JE-CV)” NCT01092507 ↗ |
| Known as | JE-CV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01092507 ↗ |
| Modality | Vaccine | “The live, attenuated Japanese encephalitis (JE) chimeric virus vaccine (JE-CV)” PMID 24717964 ↗ Jun 2014 |